Salix's AIDS/HIV-related diarrhea drug Fulyzaq gets FDA nod

01/1/2013 | Reuters · American City Business Journals

Salix Pharmaceuticals' Fulyzaq, or crofelemer, has been approved by the FDA to treat diarrhea in HIV/AIDS patients undergoing antiretroviral therapy. This makes Fulyzaq, developed by Napo Pharmaceuticals, the first approved treatment for HIV/AIDS patients whose diarrhea is not caused by bacteria, virus or parasite.

View Full Article in:

Reuters · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ